We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-2.10 | -1.41% | 146.43 | 149.58 | 146.33 | 149.37 | 7,642,733 | 00:53:34 |
By Colin Kellaher
Genmab A/S on Thursday said a phase 3 study of the cancer drug Darzalex met its primary endpoint in the most common type of amyloidosis, a rare disease that occurs when an abnormal protein called amyloid builds up in a body's tissues and organs.
The Copenhagen biotechnology company said subcutaneous Darzalex in combination with cyclophosphamide, bortezomib and dexamethasone for patients with newly diagnosed light-chain amyloidosis met the primary endpoint of percentage of patients with hematologic complete response.
Genmab said the study was conducted by Johnson & Johnson's Janssen Biotech Inc. unit, which has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement.
Genmab said Janssen will discuss with health authorities the potential for a regulatory submission for the indication, adding that there are currently no approved treatments for the progressive disease.
Darzalex is already approved in several indications in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.
U.S.-listed shares of Genmab were recently up 4.6% to $31.06. Johnson & Johnson shares gained 2.1% to $147.90.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 28, 2020 14:26 ET (18:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions